Literature DB >> 11892834

Insulators coupled to a minimal bidirectional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain.

H L Fitzsimons1, J M Mckenzie, M J During.   

Abstract

Recombinant AAV is increasingly becoming the vector of choice for many gene therapy applications in the CNS, due to its lack of toxicity and high level of sustained expression. With recent improvements in the generation of pure, high titer vector stocks, the regulation of gene expression is now a key issue for successful translation of gene therapy-based treatments to the clinic. The level of the transgene protein may need to be maintained within a narrow therapeutic window for the successful treatment of human disease. The doxycycline responsive system directs a dose-responsive, tightly regulated level of gene expression and has been used successfully in transgenic mouse models. Here, we have optimized an autoregulatory, bidirectional doxycyline responsive cassette specifically for use in rAAV. We minimized the size of the cassette and decreased the basal leakiness of the system, leading to tight regulation in the rat

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11892834     DOI: 10.1038/sj.gt.3301582

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  15 in total

Review 1.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

Review 2.  Strategies for targeting primate neural circuits with viral vectors.

Authors:  Yasmine El-Shamayleh; Amy M Ni; Gregory D Horwitz
Journal:  J Neurophysiol       Date:  2016-04-06       Impact factor: 2.714

3.  The assessment of adeno-associated vectors as potential intrinsic treatments for brainstem axon regeneration.

Authors:  Ryan R Williams; Damien D Pearse; Patrick A Tresco; Mary Bartlett Bunge
Journal:  J Gene Med       Date:  2012-01       Impact factor: 4.565

4.  Long-term inducible expression in striatal neurons from helper virus-free HSV-1 vectors that contain the tetracycline-inducible promoter system.

Authors:  Qingshen Gao; Mei Sun; Xiaodan Wang; Guo-Rong Zhang; Alfred I Geller
Journal:  Brain Res       Date:  2006-03-20       Impact factor: 3.252

5.  Doxycycline regulation in a single retroviral vector by an autoregulatory loop facilitates controlled gene expression in liver cells.

Authors:  Florian Kühnel; Corinna Fritsch; Sabine Krause; Bettina Mundt; Thomas Wirth; Yasmin Paul; Nisar Peter Malek; Lars Zender; Michael Peter Manns; Stefan Kubicka
Journal:  Nucleic Acids Res       Date:  2004-02-13       Impact factor: 16.971

6.  Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta.

Authors:  D H Meijer; C A Maguire; S G LeRoy; M Sena-Esteves
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

7.  Current status of transcriptional regulation systems.

Authors:  Tobias May; Hansjörg Hauser; Dagmar Wirth
Journal:  Cytotechnology       Date:  2006-05-20       Impact factor: 2.058

8.  Construction of a single lentiviral vector containing tetracycline-inducible Alb-uPA for transduction of uPA expression in murine hepatocytes.

Authors:  Jiasi Bai; Jungang Li; Qing Mao
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  RANGE: Gene Transfer of Reversibly Controlled Polycistronic Genes.

Authors:  Yiwei Chen; Liji Cao; Chonglin Luo; Désirée Aw Ditzel; Jörg Peter; Rolf Sprengel
Journal:  Mol Ther Nucleic Acids       Date:  2013-04-09       Impact factor: 10.183

10.  Regulated expression of lentivirus-mediated GDNF in human bone marrow-derived mesenchymal stem cells and its neuroprotection on dopaminergic cells in vitro.

Authors:  Wei-Hua Yang; Chun Yang; Yue-Qiang Xue; Tao Lu; Jakob Reiser; Li-Ru Zhao; Wei-Ming Duan
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.